0VQA.LSE Viking Therapeutics, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -106.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0VQA.LSE undervalued?
Graham numberThe Graham number of Viking Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Viking Therapeutics, Inc. fundamental analysis
No fundamental analysis for Viking Therapeutics, Inc. yet.
Viking Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available no…
Full company profileViking Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Viking Therapeutics, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Gross Profit | - | - | - | -260K | -277K | -296K | -291K | -292K | -346K | -431K | - |
| Operating Income | -13.8M | -19.1M | -26.2M | -32.7M | -42.7M | -55.7M | -70.4M | -101M | -151M | -393M | -645M |
| EBITDA | -10.8M | -15.8M | -20.3M | -25.4M | -39.1M | -54.7M | -68.5M | -85.5M | -110M | -393M | -645M |
| Net Income | -14.7M | -20.6M | -22.1M | -25.8M | -39.5M | -55.0M | -68.9M | -85.9M | -110M | -360M | -626M |
| EPS | -0.74 | -0.69 | -0.38 | -0.36 | -0.54 | -0.71 | -0.90 | -0.91 | -1.01 | -3.19 | -5.30 |
| Balance Sheet | |||||||||||
| Total Assets | 14.5M | 22.1M | 302M | 284M | 257M | 211M | 169M | 368M | 908M | 716M | 977M |
| Total Liabilities | 6.49M | 8.66M | 4.56M | 7.14M | 12.2M | 8.78M | 23.2M | 20.1M | 28.0M | 76.7M | 389M |
| Shareholders' Equity | 8.04M | 13.5M | 298M | 277M | 244M | 202M | 145M | 348M | 880M | 639M | 589M |
| Cash & Short-term Investments | 13.2M | 20.6M | 302M | 276M | 248M | 202M | 155M | 362M | 903M | 706M | 960M |
| Total Debt | 3.27M | 3.45M | - | 662K | 359K | 29.0K | 1.56M | 936K | 1.12M | 137K | 255M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.1M | -14.8M | -18.8M | -24.8M | -21.8M | -47.6M | -48.4M | -73.4M | -87.8M | -279M | -503M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -11.1M | -14.8M | -18.8M | -24.8M | -21.8M | -47.6M | -48.4M | -73.4K | -87.8M | -279M | -503M |
| Ratios | |||||||||||
| ROE | -183.2% | -152.8% | -7.4% | -9.3% | -16.2% | -27.2% | -47.4% | -24.7% | -12.5% | -56.3% | -106.4% |
| ROA | -101.3% | -93.0% | -7.3% | -9.1% | -15.4% | -26.1% | -40.9% | -23.3% | -12.1% | -50.2% | -64.1% |
| Debt to Equity | 0.41x | 0.26x | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x | 0.00x | 0.43x |
What these items mean
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Viking Therapeutics, Inc. dividends
Viking Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Who owns Viking Therapeutics, Inc.
- Insiders 2.83%
- Institutions 60.24%
- Public & others 36.93%
- Free float 125M
Viking Therapeutics, Inc. company profile
- Company name
- Viking Therapeutics, Inc.
- Ticker
- 0VQA.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 74
- Fiscal year end
- December
- Address
- 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
- Phone
- 858 704 4660
- Website
- vikingtherapeutics.com
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Viking Therapeutics, Inc. management
8- Dr. Brian Lian Ph.D.President, CEO & Director · born 1966
- Mr. Gregory S. Zante CPAChief Financial Officer · born 1971
- Mr. Michael MorneauVice President of Finance & Administration · born 1965
- Ms. Katherine MercierVice President of Quality & Compliance
- Mr. Kenneth J. Herman M.B.A.Senior Vice President of Commercial, Marketing & Sales
- Dr. Geoffrey E. Barker Ph.D.Chief Development Officer
- Dr. Nils U. Olsson Ph.D.Senior Vice President of Technical Operations
- Dr. Hubert C. Chen M.D., M.P.H.Chief Medical Officer · born 1969